# Open-Label Extension and Safety Study of Talazoparib

> **NCT02921919** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 120 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT02921919
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-08
- **Primary completion:** 2021-07-20
- **Final completion:** 2021-07-20
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921919, "Open-Label Extension and Safety Study of Talazoparib". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02921919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*